News
Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...
Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...
Bayer has inked a global licensing deal with Kumquat Biosciences for a KRAS G12D cancer drug, allowing Phase 1a trials to be ...
The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...
Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology
Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced ...
Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.
BERLIN (Reuters) -German pharmaceutical group Bayer announced on Tuesday a deal worth up to $1.3 billion with Kumquat ...
For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...
The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...
With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results